A drug described as "the closest we have ever been to an HIV vaccine" that currently costs over $40,000 per a person per a year, could be made to cost less than $40 for each patient, researchers said on Tuesday.
Early trials have found, Lenacapavir, developed by US pharmaceutical company Gilead, to be nearly 100 percent effective in preventing HIV infection. The drug is also easier to administer than current preventative regimens that require daily pills, with Lenacapavir needing only two injections per year.